Immunic, Inc. · NASDAQ:IMUX
Immunic — Q1 2024 Earnings Presentation
17 slides from Immunic's earnings presentation, May 8, 2024
Slide 1: Immunic Therapeutics First Quarter 2024 Financial Results and Corporate Update
Immunic Therapeutics First Quarter 2024 Financial Results and Corporate Update NASDAQ: IMUX | May 8, 2024
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Slide 3: Agenda
Agenda First Quarter 2024 Financial Results and Corporate Update 01 First Quarter 2024 and Subsequent Highlights 04 Q&A Session 02 Financial and Operating Results 05 Summary and Highlights 03 Clinical Development Programs 3 | © Immunic, Inc. | May/08/2024
Slide 4: First Quarter 2024 and Subsequent Highlights
01 First Quarter 2024 and Subsequent Highlights
Slide 5: January: Three-Tranche Private Placement of up to $240M, Cash Runway Extended
January: Three-Tranche Private Placement of up to $240M, Cash Runway Extended Into Q3/2025 Based on Initial $80M Tranche § First tranche was an upfront payment of $80 million at $1.43 per share § Second tranche is a conditional mandatory purchase of an additional $80 million at $1.716 per share – Re
Slide 6: February: Presented Data From Phase 2 CALLIPER and CALVID-1 Trials at ACTRIMS
February: Presented Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 (February 29-March 2 in West Palm Beach, FL) CALLIPER Interim Analysis: Clear Separation CALVID-1: Potential Contribution to the in NfL Levels Across All PMS Patients Reduction of Fat
Slide 7: March: Data Presentations at Frontiers in Medicinal Chemistry and Society for Virology
March: Data Presentations at Frontiers in Medicinal Chemistry and 33rd Annual Meeting of the Society for Virology Vidofludimus Calcium Potently Activates Potent Broad-Spectrum Antiviral Neuroprotective Transcription Factor Nurr1 Activity In Vitro § March 17-20 in Munich, Germany § March 25-28 in Vie
Slide 8: March: Received Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in MS
March: Received Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in MS Notice of Allowance from the USPTO for patent application 16/981,122, covering the composition- of-matter of a specific polymorph of vidofludimus calcium and a related method of production of the material Claims are exp
Slide 9: April: Hosted In-Person Multiple Sclerosis R&D Day in San Francisco
April: Hosted In-Person Multiple Sclerosis R&D Day in San Francisco Could Vidofludimus Calcium be the First Neuroprotective Treatment Option for Multiple Sclerosis? Immunic speakers: § Daniel Vitt, PhD, CEO & President § Hella Kohlhof, PhD, CSO § Andreas Muehler, MD, CMO Attending expert: § Zuoming
Slide 10: Financial and Operating Results
02 Financial and Operating Results
Slide 11: Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts, unaudited) Three Months Ended March 31, 2024 2023 Operating expenses: Research and development $ 18,736 $ 22,963 General and administrative 5,145 4,288 Total operating expenses 23,881 27,251 Loss from
Slide 12: Clinical Development Programs
03 Clinical Development Programs
Slide 13: Several Clinical Value Inflection Points Ahead
Several Clinical Value Inflection Points Ahead IMU-838 § Top-line data from phase 2 CALLIPER trial in PMS expected in April 2025 § Interim, non-binding futility analysis of phase 3 IMU-838 ENSURE program expected in late 2024 in RMS § Readout of first phase 3 ENSURE trial anticipated in Q2/2026, sec
Slide 14: Q&A Session
04 Q&A Session
Slide 15: Summary and Highlights
05 Summary and Highlights
Slide 16: Advanced Clinical Pipeline
Advanced Clinical Pipeline Well Differentiated Programs in Various Phases of Clinical Development Program Preclinical Phase 1 Phase 2 Phase 3 Relapsing Multiple Sclerosis (RMS) – ENSURE Trials Vidofludimus Calcium Progressive Multiple Sclerosis (PMS) – CALLIPER Trial (IMU-838) Ulcerative Colitis (UC
Slide 17: Thank You!
Thank You! Immunic, Inc. Immunic AG 1200 Avenue of the Americas Lochhamer Schlag 21 New York City, NY 10036 82166 Gräfelfing (Munich) USA Germany Jessica Breu Vice President Investor Relations & Communications Immunic Australia Pty. Ltd. Melbourne Phone: +49-89-2080477-09 Australia Email: ir@imux.co